CD4+ T cell responses to cytomegalovirus in early life: A prospective birth cohort study

David J.C. Miles; Marianne Van Der Sande; Steve Kaye; Sarah Crozier; Olubukola Ojuola; Melba S. Palmero; Mariama Sanneh; Ebrima S. Touray; Pauline Waight; Sarah Rowland-Jones; Hilton Whittle; Arnaud Marchant

doi:10.1086/527418

CD4⁺ T cell responses to cytomegalovirus in early life: A prospective birth cohort study

David J.C. Miles
, Marianne Van Der Sande
, Steve Kaye
, Sarah Crozier
, Olubukola Ojuola
, Melba S. Palmero
, Mariama Sanneh
, Ebrima S. Touray
, Pauline Waight
, Sarah Rowland-Jones
, Hilton Whittle
, Arnaud Marchant

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

Abstract

We compared cytomegalovirus (CMV)-specific interferon-γ (IFN-γ), interleukin 2 (IL-2), and CD154 CD4⁺ T cell responses of infants to those from chronically infected adults and from children aged 4-5 years. Magnitudes of the responses were similar, although coexpression of IFN-γ plus CD154 occurred more than coexpression of IFN-γ plus IL-2 or IL-2 plus CD154. Responses remained constant during infancy, although the proportion of IFN-γ-producing cells increased from infancy to adulthood. Most responding cells in infants were undifferentiated (i.e., CD27 ⁺CD28⁺), although IFN-γ-producing cells were disproportionately CD27^-. By 12 months after diagnosis, viremia was rarely detectable, indicating that CMV was controlled despite the slow development of CMV-specific CD4⁺ T cell responses.

Original language	English
Pages (from-to)	658-662
Number of pages	5
Journal	Journal of Infectious Diseases
Volume	197
Issue number	5
DOIs	https://doi.org/10.1086/527418
Publication status	Published - 1 Mar 2008
Externally published	Yes

Bibliographical note

Funding Information:
1Medical Research Council Laboratories Gambia, Banjul, the Gambia; 2National Institute for Public Health and the Environment, Bilthoven, the Netherlands; 3Jefferiss Trust Laboratory, Imperial College London, and 4Immunisation Department, Health Protection Agency Centre for Infections, London, United Kingdom; 5Department of Pediatrics, Bronx Lebanon Hospital Center, Bronx, New York; and 6Institute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium

Funding Information:
Received 30 July 2007; accepted 25 September 2007; electronically published 20 February 2008. Potential conflicts of interest: none reported. Financial support: GSK Biologicals, the Medical Research Council (SCC885, L2003-4), and Fonds National de la Recherche Scientifique, Belgium (to A.M.). a Current affiliation: MLW Clinical Research Programme, Blantyre, Malawi. Reprints or correspondence: Prof. David Miles, MLW Clinical Research Programme, PO Box 30096, Chichiri, Blantyre 3, Malawi ([email protected]).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1086/527418

Cite this

@article{0f46f8a4bb3d46dc8643b0331b43e070,

title = "CD4+ T cell responses to cytomegalovirus in early life: A prospective birth cohort study",

abstract = "We compared cytomegalovirus (CMV)-specific interferon-γ (IFN-γ), interleukin 2 (IL-2), and CD154 CD4+ T cell responses of infants to those from chronically infected adults and from children aged 4-5 years. Magnitudes of the responses were similar, although coexpression of IFN-γ plus CD154 occurred more than coexpression of IFN-γ plus IL-2 or IL-2 plus CD154. Responses remained constant during infancy, although the proportion of IFN-γ-producing cells increased from infancy to adulthood. Most responding cells in infants were undifferentiated (i.e., CD27 +CD28+), although IFN-γ-producing cells were disproportionately CD27-. By 12 months after diagnosis, viremia was rarely detectable, indicating that CMV was controlled despite the slow development of CMV-specific CD4+ T cell responses.",

author = "Miles, \{David J.C.\} and \{Van Der Sande\}, Marianne and Steve Kaye and Sarah Crozier and Olubukola Ojuola and Palmero, \{Melba S.\} and Mariama Sanneh and Touray, \{Ebrima S.\} and Pauline Waight and Sarah Rowland-Jones and Hilton Whittle and Arnaud Marchant",

note = "Funding Information: 1Medical Research Council Laboratories Gambia, Banjul, the Gambia; 2National Institute for Public Health and the Environment, Bilthoven, the Netherlands; 3Jefferiss Trust Laboratory, Imperial College London, and 4Immunisation Department, Health Protection Agency Centre for Infections, London, United Kingdom; 5Department of Pediatrics, Bronx Lebanon Hospital Center, Bronx, New York; and 6Institute for Medical Immunology, Universit{\'e} Libre de Bruxelles, Charleroi, Belgium Funding Information: Received 30 July 2007; accepted 25 September 2007; electronically published 20 February 2008. Potential conflicts of interest: none reported. Financial support: GSK Biologicals, the Medical Research Council (SCC885, L2003-4), and Fonds National de la Recherche Scientifique, Belgium (to A.M.). a Current affiliation: MLW Clinical Research Programme, Blantyre, Malawi. Reprints or correspondence: Prof. David Miles, MLW Clinical Research Programme, PO Box 30096, Chichiri, Blantyre 3, Malawi ([email protected]).",

year = "2008",

month = mar,

day = "1",

doi = "10.1086/527418",

language = "English",

volume = "197",

pages = "658--662",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - CD4+ T cell responses to cytomegalovirus in early life

T2 - A prospective birth cohort study

AU - Miles, David J.C.

AU - Van Der Sande, Marianne

AU - Kaye, Steve

AU - Crozier, Sarah

AU - Ojuola, Olubukola

AU - Palmero, Melba S.

AU - Sanneh, Mariama

AU - Touray, Ebrima S.

AU - Waight, Pauline

AU - Rowland-Jones, Sarah

AU - Whittle, Hilton

AU - Marchant, Arnaud

N1 - Funding Information: 1Medical Research Council Laboratories Gambia, Banjul, the Gambia; 2National Institute for Public Health and the Environment, Bilthoven, the Netherlands; 3Jefferiss Trust Laboratory, Imperial College London, and 4Immunisation Department, Health Protection Agency Centre for Infections, London, United Kingdom; 5Department of Pediatrics, Bronx Lebanon Hospital Center, Bronx, New York; and 6Institute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium Funding Information: Received 30 July 2007; accepted 25 September 2007; electronically published 20 February 2008. Potential conflicts of interest: none reported. Financial support: GSK Biologicals, the Medical Research Council (SCC885, L2003-4), and Fonds National de la Recherche Scientifique, Belgium (to A.M.). a Current affiliation: MLW Clinical Research Programme, Blantyre, Malawi. Reprints or correspondence: Prof. David Miles, MLW Clinical Research Programme, PO Box 30096, Chichiri, Blantyre 3, Malawi ([email protected]).

PY - 2008/3/1

Y1 - 2008/3/1

N2 - We compared cytomegalovirus (CMV)-specific interferon-γ (IFN-γ), interleukin 2 (IL-2), and CD154 CD4+ T cell responses of infants to those from chronically infected adults and from children aged 4-5 years. Magnitudes of the responses were similar, although coexpression of IFN-γ plus CD154 occurred more than coexpression of IFN-γ plus IL-2 or IL-2 plus CD154. Responses remained constant during infancy, although the proportion of IFN-γ-producing cells increased from infancy to adulthood. Most responding cells in infants were undifferentiated (i.e., CD27 +CD28+), although IFN-γ-producing cells were disproportionately CD27-. By 12 months after diagnosis, viremia was rarely detectable, indicating that CMV was controlled despite the slow development of CMV-specific CD4+ T cell responses.

AB - We compared cytomegalovirus (CMV)-specific interferon-γ (IFN-γ), interleukin 2 (IL-2), and CD154 CD4+ T cell responses of infants to those from chronically infected adults and from children aged 4-5 years. Magnitudes of the responses were similar, although coexpression of IFN-γ plus CD154 occurred more than coexpression of IFN-γ plus IL-2 or IL-2 plus CD154. Responses remained constant during infancy, although the proportion of IFN-γ-producing cells increased from infancy to adulthood. Most responding cells in infants were undifferentiated (i.e., CD27 +CD28+), although IFN-γ-producing cells were disproportionately CD27-. By 12 months after diagnosis, viremia was rarely detectable, indicating that CMV was controlled despite the slow development of CMV-specific CD4+ T cell responses.

UR - https://www.scopus.com/pages/publications/40549097037

U2 - 10.1086/527418

DO - 10.1086/527418

M3 - Article

C2 - 18279047

AN - SCOPUS:40549097037

SN - 0022-1899

VL - 197

SP - 658

EP - 662

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 5

ER -